Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Marie Skłodowska-Curie Action · Running

DREAM The pharmaco-microbiomics of depression

Coordinator
Johann Wolfgang Goethe-Universitaet Frankfurt Am Main, Germany
Runs
1 September 2023 to 31 October 2026
Status
Running
EU funding
€237k
Total cost
—
Partners
3 organisations in 2 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101065387

What the project is doing

In the project's own words, from its summary on CORDIS.

This interdisciplinary project aims to improve response to depression treatment using the gut microbiota. About one third of patients with depression do not respond to treatment with Selective-Serotonin-Reuptake-Inhibitors (SSRIs). Moreover, side effects such as gastrointestinal complaints are common. The commensal gut microbiota, residing in the human intestinal tract in trillions, likely contribute to variation in treatment efficacy.

This makes them a promising candidate to improve treatment response. The highly inter-individual variable gut bacteria collectively represent an enormous amount of genes, enzymes and transporters (outnumbering human genes by 10-100 times). Hereby, the gut microbiota are involved in processing of orally ingested compounds, and, through the communication highway called the gut-brain-axis, interact with the central nervous system.

Anti-depressant medication such as SSRIs reduce gut microbial diversity and change community dynamics. For example, in vitro studies have shown unintentional effects of SSRIs in the gut on a bacterium with a human-analogous serotonin transporter. This negatively affects serotonin metabolism in the gut, potentially contributing to side effects and reduced treatment response. Other similar mechanisms may occur, yet very limited experimental experimental data exist mapping which and how gut microbiota are impacted by SSRIs.

Moreover, hardly any studies link SSRI medication induced gut microbial effects to treatment response. Using clinical cohorts, I will dissociate gut microbial profiles of patients responding versus not responding to their SSRI medication. In a culturing experiment, fecal material of such responders and non-responders will be characterized in terms of growth profile after SSRI exposure, transcriptomic and metabolomics.

Using these results, a probiotics product will be developed. This project contains clinical, microbial and applied work with great societal and economic potential.

Topics

Who is involved

OrganisationCityCountryRole
Johann Wolfgang Goethe-Universitaet Frankfurt Am MainFrankfurt Am MainGermanyCoordinator
Eberhard Karls Universitaet TuebingenTuebingenGermanyAssociatedpartner
Winclove Holding BVAmsterdamNetherlandsAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI